martes, 6 de octubre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· October 31, 2025

The Zacks Analyst Blog Highlights Broadcom, Johnson & Johnson, Palantir Technologies, Fossil Group and Moving iMage

View original at finance.yahoo.com
The Zacks Analyst Blog Highlights Broadcom, Johnson & Johnson, Palantir Technologies, Fossil Group and Moving iMage For Immediate Release Chicago, IL – October 31, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Management guides for further margin gains as SG&A savings and licensing efficiencies take hold

    80% confidence

  • J&J has rapidly advanced its pipeline this year that will help drive growth through the back half of the decade

    80% confidence

  • The turnaround plan targets $30 million in FY25 savings through supply chain, pricing and vendor initiatives

    80% confidence

  • Roughly more than 90% of Broadcom's largest 10,000 customers have adopted VCF as of fiscal third quarter

    80% confidence

  • Since 2000, Zacks' top stock-picking strategies have blown away the S&P's +7.7% average gain per year with average gains of +48.4%, +50.2% and +56.7% per year

    80% confidence

  • Broadcom expects fourth-quarter fiscal 2025 AI revenues to jump 66% year over year to $6.2 billion

    80% confidence

  • J&J expects sales growth in both segments to be higher in 2026

    80% confidence

  • Gross margins in fiscal fourth quarter are expected to contract sequentially

    80% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,985
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,985 hechos verificados con la fuente5,351 documentos fuente archivados
Consulta estos datos → isubstrate.com
The Zacks Analyst Blog Highlights Broadcom, Johnson & Johnson, Palantir Technologies, Fossil Group and Moving iMage — Source | Via News | es.VIA.NEWS